A comparison of the safety and efficacy of ondansetron versus granisetron as prophylaxis against chemo/ radiotherapy-induced nausea and vomiting in bone marrow transplantation patients. A double-blinded,randomized,prospective,pilot study
Restricted accessOtherFirst published online March, 1997
A comparison of the safety and efficacy of ondansetron versus granisetron as prophylaxis against chemo/ radiotherapy-induced nausea and vomiting in bone marrow transplantation patients. A double-blinded,randomized,prospective,pilot study
Introduction. Nausea and vomiting (N&V) are well known and distressing side effects of chemoradio therapy. Conditioning protocols for patients undergo ing bone marrow transplantation (BMT) consist of highly emetogenic high-dose chemotherapy with or without total body irradiation (TBI). The 5HT3 (sero tonin receptor) antagonists heralded a marked im provement in controlling chemotherapy-induced N&V. Ondansetron and granisetron have been avail able for some time with limited information available concerning their pharmacological and pharmacoeco nomic differences and patient acceptability.
Patients and Methods. This pilot study initiated comparison of the two drugs and evaluated the antiemetic efficacy and safety of a single daily dose of ondansetron, 16 mg, plus dexamethasone, 10 mg, compared to granisetron, 3 mg, plus dexamethasone, 10 mg, in patients receiving high dose chemotherapy (±TBI), prior to BMT. The 12-month pilot study was double-blinded, randomized, and prospective. A non- homogenous cohort of 23 patients (10 receiving ondansetron and 13 granisetron) were enrolled.
Results. No significant differences in the efficacy of the two protocols were observed. In each arm about 50% of the patients had a complete response, and a similar number had a major response.
Side Effects. The most common adverse events reported during the study included diarrhea and head ache. No patients were withdrawn due to side effects.
Conclusions. Our preliminary findings suggest that both of these two antiemetic protocols are safe and similarly effective in preventing chemotherapy-induced emesis in patients receiving BMT conditioning.
Discussion. Further evaluation in a multicenter study should now be made to compare efficacy, safety, cost-effectiveness, and quality of life parame ters of these two drugs.
Schmoll HJOndansetron—a new concept in anti-emetic therapy: the clinical challenge . Eur J Cancer.1991;27(Suppl. 1):51-52.
2.
Anon: 5HT3 receptor antagonists: a new class of antiemetics. Lancet.1987;1:1470-1471.
3.
Plosker GH, Goa KLGranisetron. A review of its pharmacological properties and therapeutic use as an antiemetic. Drugs.1991; 42(5):805-824.
4.
de Bruijn KMTropisetron: A review of the clinical experience . Drugs.1992;43(Suppl. 3):11-22.
5.
Tyers MG, Bunch KT, Humphrey Ppa.Pharmacological and antiemetic properties of ondansetron. Eur J Cancer Clin Oncol.1989;25(Suppl 1):515-519.
6.
Polliack A.A Handbook of Essential Drugs and Regimens in Hematological Oncology . Reading, Berks, UK: Harwood Academic Publishers GmbH ; 1989.
7.
Dogliotti L. , Antonacci RA, Raze E., Ortega C., Berruiti A., Faggiuola R.Three years' experience with tropisetron with control of nausea and vomiting in cisplatin-treated patients. Drugs.1992;4B(suppl 3):6-10.
8.
Marschner N.Antiemetic control with ondansetron in the chemotherapy of breast cancer: a review. Eur J Cancer.1991;27(Suppl 1):515-517.
9.
Didiel R., Cuppsol B., Caubel M.The efficacy of granisetron as a. prophylactic anti-emetic and intervention agent in high-dose cisplatin induced emesis. Eur J Cancer.1990;26(Suppl. 1):523-527.
10.
Morrow G., Hickok J., Rosental S.Progress in reducing nauseau and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril) and tropisetron (Navoban). Cancer.1996;76:343-357
11.
Andrews Plr , Bhandari P., Davey PT, Bingham S., Marr HE, Blower PRAre all 5-HT3 receptor antagonists the same ? Eur J Cancer.1992;28(Suppl 1):52-56.
12.
Hewitt M., Cornish J., Pamphilon D., Oakhill A.Effective emetic control during conditioning of children for bone marrow transplantation using ondansetron, a 5-HT3 antagonist. Bone Marrow Transplant.1991;7:431-433.
13.
Hunter AE, Prentice HG, Pothecary K., et al. Granisetron, a selective 5HT3 receptor antagonist for the prevention of radiation induced emesis during total body irradiation. Bone Marrow Transplant.1991;7:439-441.
14.
Sorbe B., Berglind AMTropisetron, a new 5HT3 receptor antagonist in the prevention of radiation-induced nausea, vomiting and diarrhea. Drugs.1992 :43(suppl. 3):33-39.
15.
Bregni M., Siene S., DiNicola M., Bonadonna G., Gianni AMTropisetron plus haloperidol to ameliorate nausea and vomiting associated with high dose alkylat-ing agent cancer chemotherapy. Eur J Cancer.1991;271:561-565.
16.
Or R., Drakos P., Nagler A., Naparstek E., Kapaluchnik J., Cass Y.The antiemetic efficacy and tolerability of tropisetron in patients conditioned with high-dose chemotherapy (with and without total body irradiation) prior to bone marrow transplantation. Support Care Cancer.1994;2:245-248.
17.
Kris MG, Gralla RZ, Tyron LB, Clark RA, Kelsen Dp, et al. Improved control of cisplatin-induced emesis with high dose metoclopramide and with combinations of metoclopramide, dexamethasone and diphenhydrmine. Cancer.1985;55A:527-534.
18.
Blume KG: Marrow transplantation. In: Hematology. New York: McGraw Hill;1990:1674-1685.
